Year Founded
2019
Ownership
Private
Employees
~10
Therapeutic Areas
OncologyImmunology
Stage
Phase 2
Modalities
DNA-based therapeutics

CureLab Oncology General Information

Completed Phase I/IIa clinical trials showing high safety profile and clinical benefits. Phase II trials ongoing outside US, preparing for US Phase II trials.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

Elenagen
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to CureLab Oncology's pipeline data

Book a demo

Key Partnerships

Aldevron

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

CureLab Oncology Funding

Deal TypeDateAmountStatusStage
Later Stage VCDec 22, 2022$3.0MCompletedPhase 2
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view CureLab Oncology's complete valuation and funding history, request access »

CureLab Oncology Investors

John Ballantyne
Investor Type: Venture Capital
Holding: Minority